Low concentration of arsenic-induced aberrant mitosis in keratinocytes through E2F1 transcriptionally regulated aurora-A

Toxicological Sciences

Volumn 132, Issue 1, 2013, Pages 43-52

  Wu, Chin Han ^a,b   Tseng, Ya Shih ^c   Kao, Yu Ting ^a   Sheu, Hamm Ming ^a   Liu, Hsiao Sheng ^a,d  

^a Institute of Molecular and Cellular Biology   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Arsenic; Aurora A; Keratinocyte; Mitosis

Indexed keywords

ARSENIC; AURORA A KINASE; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CENTROMERE; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KERATINOCYTE; MITOSIS; MULTINUCLEAR CELL; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; E2F1 TRANSCRIPTION FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MITOSIS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876473676     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs322     Document Type: Article

References (39)

1. Bi, X., Gu, J., Guo, Z., Tao, S., Wang, Y., Tang, L., Wu, J., and Mi, Q. (2010). Different pathways are involved in arsenic-trioxide-induced cell proliferation and growth inhibition in human keratinocytes. Skin Pharmacol. Physiol. 23, 68-78.
2. Chang, C. H., Tsai, R. K., Chen, G. S., Yu, H. S., and Chai, C. Y. (1998). Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers. J. Cutan. Pathol. 25, 457-462.
3. Chien, C. W., Chiang, M. C., Ho, I. C., and Lee, T. C. (2004). Association of chromosomal alterations with arsenite-induced tumorigenicity of human HaCaT keratinocytes in nude mice. Environ. Health Perspect. 112, 1704-1710.
4. Crosio, C., Fimia, G. M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C. D., and Sassone-Corsi, P. (2002). Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 22, 874-885.
5. Dutertre, S., Descamps, S., and Prigent, C. (2002). On the role of Aurora-A in centrosome function. Oncogene 21, 6175-6183.
6. Ganem, N. J., Godinho, S. A., and Pellman, D. (2009). A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278-282.
7. Gritsko, T. M., Coppola, D., Paciga, J. E., Yang, L., Sun, M., Shelley, S. A., Fiorica, J. V., Nicosia, S. V., and Cheng, J. Q. (2003). Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin. Cancer Res. 9, 1420-1426.
8. He, L., Yang, H., Ma, Y., Pledger, W. J., Cress, W. D., and Cheng, J. Q. (2008). Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J. Biol. Chem. 283, 31012-31020.
9. Hsu, C. H., Yang, S. A., Wang, J. Y., Yu, H. S., and Lin, S. R. (1999). Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br. J. Cancer 80, 1080-1086.
10. Ivanova, I. A., D'Souza, S. J., and Dagnino, L. (2005). Signalling in the epidermis: The E2F cell cycle regulatory pathway in epidermal morphogenesis, regeneration and transformation. Int. J. Biol. Sci. 1, 87-95.
11. Jeng, Y. M., Peng, S. Y., Lin, C. Y., and Hsu, H. C. (2004). Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. 10, 2065-2071.
12. Kollareddy, M., Zheleva, D., Dzubak, P., Brahmkshatriya, P. S., Lepsik, M., and Hajduch, M. (2012). Aurora kinase inhibitors: Progress towards the clinic. Invest. New Drugs 30, 2411-2432.
13. Kwong, R. A., Nguyen, T. V., Bova, R. J., Kench, J. G., Cole, I. E., Musgrove, E. A., Henshall, S. M., and Sutherland, R. L. (2003). Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clin. Cancer Res. 9(10 Pt 1), 3705-3711.
14. Lassus, H., Staff, S., Leminen, A., Isola, J., and Butzow, R. (2011). Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol. Oncol. 120, 11-17.
15. Lehman, T. A., Modali, R., Boukamp, P., Stanek, J., Bennett, W. P., Welsh, J. A., Metcalf, R. A., Stampfer, M. R., Fusenig, N., and Rogan, E. M. (1993). p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 14, 833-839.
16. Lei, Y., Yan, S., Ming-De, L., Na, L., and Rui-Fa, H. (2011). Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem. 113, 514-518.
17. Lentini, L., Amato, A., Schillaci, T., and Di Leonardo, A. (2007). Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype. BMC Cancer 7, 212.
18. Liao, W. T., Chang, K. L., Yu, C. L., Chen, G. S., Chang, L. W., and Yu, H. S. (2004). Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J. Invest. Dermatol. 122, 125-129.
19. Liao, W. T., Lan, C. C., Lee, C. H., and Yu, H. S. (2011). Concentrationdependent cellular responses of arsenic in keratinocytes. Kaohsiung J. Med. Sci. 27, 390-395.
20. Liao, W. T., Lin, P., Cheng, T. S., Yu, H. S., and Chang, L. W. (2007). Arsenic promotes centrosome abnormalities and cell colony formation in p53 compromised human lung cells. Toxicol. Appl. Pharmacol. 225, 162-170.
21. Liu, H. S., Ke, C. S., Cheng, H. C., Huang, C. Y., and Su, C. L. (2011). Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol. Pharmacol. 80, 638-646.
22. Lukasiewicz, K. B., and Lingle, W. L. (2009). Aurora A, centrosome structure, and the centrosome cycle. Environ. Mol. Mutagen. 50, 602-619.
23. Marumoto, T., Zhang, D., and Saya, H. (2005). Aurora-A - a guardian of poles. Nat. Rev. Cancer 5, 42-50.
24. Nigg, E. A. (2002). Centrosome aberrations: Cause or consequence of cancer progression? Nat. Rev. Cancer 2, 815-825.
25. Ochi, T., Nakajima, F., and Nasui, M. (1999). Distribution of gamma-tubulin in multipolar spindles and multinucleated cells induced by dimethylarsinic acid, a methylated derivative of inorganic arsenics, in Chinese hamster V79 cells. Toxicology 136, 79-88.
26. Pi, J., Diwan, B. A., Sun, Y., Liu, J., Qu, W., He, Y., Styblo, M., and Waalkes, M. P. (2008). Arsenic-induced malignant transformation of human keratinocytes: Involvement of Nrf2. Free Radic. Biol. Med. 45, 651-658.
27. Ren, X., McHale, C. M., Skibola, C. F., Smith, A. H., Smith, M. T., and Zhang, L. (2011). An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ. Health Perspect. 119, 11-19.
28. Rossman, T. G., and Klein, C. B. (2011). Genetic and epigenetic effects of environmental arsenicals. Metallomics 3, 1135-1141.
29. Straif, K., Benbrahim-Tallaa, L., Baan, R., Grosse, Y., Secretan, B., El Ghissassi, F., Bouvard, V., Guha, N., Freeman, C., Galichet, L., et al. (2009). A review of human carcinogens-part C: Metals, arsenic, dusts, and fibres. Lancet Oncol. 10, 453-454.
30. Sun, Y., Pi, J., Wang, X., Tokar, E. J., Liu, J., and Waalkes, M. P. (2009). Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. Toxicology 262, 162-170.
31. Suzuki, T., Miyazaki, K., Kita, K., and Ochi, T. (2009). Trivalent dimethylarsenic compound induces histone H3 phosphorylation and abnormal localization of Aurora B kinase in HepG2 cells. Toxicol. Appl. Pharmacol. 241, 275-282.
32. Tanaka, M., Ueda, A., Kanamori, H., Ideguchi, H., Yang, J., Kitajima, S., and Ishigatsubo, Y. (2002). Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J. Biol. Chem. 277, 10719-10726.
33. Torchia, E. C., Caulin, C., Acin, S., Terzian, T., Kubick, B. J., Box, N. F., and Roop, D. R. (2012). Myc, Aurora kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene 31, 2680-2690.
34. Torchia, E. C., Chen, Y., Sheng, H., Katayama, H., Fitzpatrick, J., Brinkley, W. R., Caulin, C., Sen, S., and Roop, D. R. (2009). A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors. Cancer Res. 69, 7207-7215.
35. Trouba, K. J., Wauson, E. M., and Vorce, R. L. (2000). Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 164, 161-170.
36. Tseng, Y. S., Tzeng, C. C., Huang, C. Y., Chen, P. H., Chiu, A. W., Hsu, P. Y., Huang, G. C., Wang, Y. C., and Liu, H. S. (2006). Aurora-A overexpression associates with Ha-ras codon-12 mutation and blackfoot disease endemic area in bladder cancer. Cancer Lett. 241, 93-101.
37. Yang, S. B., Zhou, X. B., Zhu, H. X., Quan, L. P., Bai, J. F., He, J., Gao, Y. N., Cheng, S. J., and Xu, N. Z. (2007). Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol. Rep. 17, 1083-1088.
38. Yeh, S., How, S. W., and Lin, C. S. (1968). Arsenical cancer of skin. Histologic study with special reference to Bowen's disease. Cancer 21, 312-339.
39. Yu, H. S., Liao, W. T., and Chai, C. Y. (2006). Arsenic carcinogenesis in the skin. J. Biomed. Sci. 13, 657-666